Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Patricia Fenton-Navarro, Eduardo Pérez-Campos, María del Socorro Pina-Canseco & Bertha Fenton-Navarro. (2017) Gaucher’s Disease and Hurler’s Syndrome in Two First Cousins. International Journal of Human Genetics 17:3, pages 109-117.
Read now
Read now
Lunawati L Bennett & Kelsey Turcotte. (2015) Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease. Drug Design, Development and Therapy 9, pages 4639-4647.
Read now
Read now
Einat B Vitner, Ayelet Vardi, Timothy M Cox & Anthony H Futerman. (2015) Emerging therapeutic targets for Gaucher disease. Expert Opinion on Therapeutic Targets 19:3, pages 321-334.
Read now
Read now
Articles from other publishers (24)
Jiao Xu, Han Bao, Xinye Qi, Jiahui Wang, Hang Yin, Chunyang Shang, Rachel Leeyin Tan, Qunhong Wu & Weidong Huang. (2021) Family caregivers of rare disease: A survey on health‐related quality of life in family caregivers for Gaucher disease patients in China. Molecular Genetics & Genomic Medicine 9:9.
Crossref
Crossref
Fatma İlknur VAROL, Ayşe SELİMOĞLU, Şükrü GÜNGÖR & Bengü MACİT. (2021) Gaucher Disease Type 1, A Rare Disease: A Single Center-ExperienceGaucher Hastalığı Tip 1, Nadir Bir Hastalık: Tek Merkez Deneyimi. Journal of Contemporary Medicine 11:2, pages 147-150.
Crossref
Crossref
Laura Rigon, Concetta De Filippis, Barbara Napoli, Rosella Tomanin & Genny Orso. (2021) Exploiting the Potential of Drosophila Models in Lysosomal Storage Disorders: Pathological Mechanisms and Drug Discovery. Biomedicines 9:3, pages 268.
Crossref
Crossref
Manasa P. Srikanth & Ricardo A. Feldman. (2020) Elevated Dkk1 Mediates Downregulation of the Canonical Wnt Pathway and Lysosomal Loss in an iPSC Model of Neuronopathic Gaucher Disease. Biomolecules 10:12, pages 1630.
Crossref
Crossref
E. P. Sysoeva, R. V. Ponomarev, K. A. Lukina, R. B. Chavynchak, S. B. Korotkova, M. V. Zhilyaeva, E. G. Nikitina, O. A. Markova, E. V. Gapchenko, A. M. Shuster, D. A. Kudlay & E. A. Lukina. (2020) Evaluation of the efficacy and safety of the biosimilar drug Glurazyme (imiglucerase) in patients with Gaucher disease type 1. Russian journal of hematology and transfusiology 65:1, pages 8-23.
Crossref
Crossref
M. B. Belogurova, Yu. V. Dinikina, D. A. Kudlay & A. Yu. Borozinets. (2020) Gaucher disease in children: what has changed in the 21st century. Russian Journal of Pediatric Hematology and Oncology 6:4, pages 19-24.
Crossref
Crossref
Mattias Andréasson, Göran Solders, Cecilia K. Björkvall, Maciej Machaczka & Per Svenningsson. (2019) Polyneuropathy in Gaucher disease type 1 and 3 – a descriptive case series. Scientific Reports 9:1.
Crossref
Crossref
Derralynn Hughes, Peter Mikosch, Nadia Belmatoug, Francesca Carubbi, TimothyM Cox, Ozlem Goker‐Alpan, Andreas Kindmark, PramodK Mistry, Ludger Poll, Neal Weinreb & Patrick Deegan. (2019) Gaucher Disease in Bone: From Pathophysiology to Practice. Journal of Bone and Mineral Research 34:6, pages 996-1013.
Crossref
Crossref
Robert A. Brown, Antanina Voit, Manasa P. Srikanth, Julia A. Thayer, Tami J. Kingsbury, Marlene A. Jacobson, Marta M. Lipinski, Ricardo A. Feldman & Ola Awad. (2019) mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cells. Disease Models & Mechanisms.
Crossref
Crossref
Bianca Marchetti. (2018) Wnt/β-Catenin Signaling Pathway Governs a Full Program for Dopaminergic Neuron Survival, Neurorescue and Regeneration in the MPTP Mouse Model of Parkinson’s Disease. International Journal of Molecular Sciences 19:12, pages 3743.
Crossref
Crossref
Josefine Blume, Stanislav Beniaminov, Cecilia Kämpe Björkvall, Maciej Machaczka & Per Svenningsson. (2017) Saccadic Impairments in Patients with the Norrbottnian Form of Gaucher’s Disease Type 3. Frontiers in Neurology 8.
Crossref
Crossref
Niti Goel & Kamali Chance. (2017) Biosimilars in rheumatology: understanding the rigor of their development. Rheumatology 56:2, pages 187-197.
Crossref
Crossref
Constanza Bondar, Maximiliano Ormazabal, Andrea Crivaro, Malena Ferreyra-Compagnucci, María Delpino, Paula Rozenfeld & Juan Mucci. (2017) Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease. International Journal of Molecular Sciences 18:1, pages 112.
Crossref
Crossref
KerriJ Kinghorn, AmirM Asghari & JorgeIván Castillo-Quan. (2017) The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease. Neural Regeneration Research 12:3, pages 380.
Crossref
Crossref
Lucy M Collins, Janelle Drouin-Ouellet, Wei-Li Kuan, Timothy Cox & Roger A Barker. (2018) Dermal fibroblasts from patients with Parkinson’s disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations. F1000Research 6, pages 1751.
Crossref
Crossref
Lucy M Collins, Janelle Drouin-Ouellet, Wei-Li Kuan, Timothy Cox & Roger A Barker. (2017) Dermal fibroblasts from patients with Parkinson’s disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations. F1000Research 6, pages 1751.
Crossref
Crossref
Kerri J. Kinghorn, Sebastian Grönke, Jorge Iván Castillo-Quan, Nathaniel S. Woodling, Li Li, Ernestas Sirka, Matthew Gegg, Kevin Mills, John Hardy, Ivana Bjedov & Linda Partridge. (2016)
A
Drosophila
Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin
. The Journal of Neuroscience 36:46, pages 11654-11670.
Crossref
Crossref
Azza Dandana, Souhaira Ben Khelifa, Hinda Chahed, Abdelhédi Miled & Salima Ferchichi. (2016) Gaucher Disease: Clinical, Biological and Therapeutic Aspects. Pathobiology 83:1, pages 13-23.
Crossref
Crossref
Derralynn A. Hughes, Derlis E. Gonzalez, Elena A. Lukina, Atul Mehta, Madhulika Kabra, Deborah Elstein, Isaac Kisinovsky, Pilar Giraldo, Ashish Bavdekar, Thomas N. Hangartner, Nan Wang, Eric Crombez & Ari Zimran. (2015) Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long‐term data from phase III clinical trials. American Journal of Hematology 90:7, pages 584-591.
Crossref
Crossref
Lucas Lopes Araújo Sousa, Moema Modesto Fonseca Rocha, Regina Ferraz Mendes & Raimundo Rosendo Prado Junior. (2014) Oral health of a child being treated for subtype I Gaucher's disease. Special Care in Dentistry 34:2, pages 100-104.
Crossref
Crossref
Katelin E. Petersen, Cynthia A. Prows, Lisa J. Martin & Koffi N. Maglo. (2014) Personalized Medicine, Availability, and Group Disparity: An Inquiry into How Physicians Perceive and Rate the Elements and Barriers of Personalized Medicine. Public Health Genomics 17:4, pages 209-220.
Crossref
Crossref
Junitsu Ito, Takafumi Saito, Chikahiko Numakura, Akiko Iwaba, Shinpei Sugahara, Rika Ishii, Chikako Sato, Hiroaki Haga, Kazuo Okumoto, Yuko Nishise, Hisayoshi Watanabe, Hiroyuki Ida, Kiyoshi Hayasaka, Hitoshi Togashi, Sumio Kawata & Yoshiyuki Ueno. (2013) A Case of Adult Type 1 Gaucher Disease Complicated by Temporal Intestinal Hemorrhage. Case Reports in Gastroenterology 7:2, pages 340-346.
Crossref
Crossref
Angela Sanders, Harmony Hemmelgarn, Heather L. Melrose, Leanne Hein, Maria Fuller & Lorne A. Clarke. (2013) Transgenic mice expressing human glucocerebrosidase variants: Utility for the study of Gaucher disease. Blood Cells, Molecules, and Diseases 51:2, pages 109-115.
Crossref
Crossref
Sean I. Savitz, Michael Benatar, Jeffrey L. Saver & Marc Fisher. (2008) Outcome Analysis in Clinical Trial Design for Acute Stroke: Physicians’ Attitudes and Choices. Cerebrovascular Diseases 26:2, pages 156-162.
Crossref
Crossref